Log in to save to my catalogue

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2306307917

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

With a 5-year minimum follow-up in patients with metastatic melanoma, overall survival at 5 years was 52% with a combination of nivolumab plus ipilimumab, as compared with 44% with nivolumab alone and 26% with ipilimumab alone. Programmed cell death ligand 1 expression did not influence the response rate or progression-free survival.

Alternative Titles

Full title

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2306307917

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2306307917

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1910836

How to access this item